Compare Amylx Pharmaceuticals Inc (AMLX) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs YieldMax COIN Option Income Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while YieldMax COIN Option Income Strategy ETF trades at $18.1. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | CONY | |
|---|---|---|
Market Cap | $2.53B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $76.50 |
52-Week Low | $7.82 | $17.80 |
Enterprise Value | $2.28B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
CONY trades at $18.54, up 4.16% today, with a bearish technical signal from moving averages but oversold RSI levels. The ETF shows no fundamental valuation ratios available, and recent news highlights significant shareholder losses despite high distribution yields. Weekly dividends are consistently announced, but underlying performance concerns persist.
Outlook remains cautious due to bearish technicals and negative media sentiment emphasizing value erosion. Risks include reliance on options income strategy and Coinbase volatility. Analyst coverage suggests skepticism, with no bullish catalysts evident near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
